Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | MGAM | O43451 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | SI | P14410 | 1/20 | 0.32 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | CRHBP | P24387 | 1/20 | 0.30 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6448431 | 0.87 | TSHR (0.41) | KMT2ATSHRALDH1A1LMNAMAPT | |
| SCHEMBL3958590 | 0.86 | GAA (0.41) | KMT2AMEN1MGAMGAASI | |
| SCHEMBL3956970 | 0.84 | TSHR (0.34) | GAATSHRALDH1A1MAPT | |
| SCHEMBL3962659 | 0.84 | PTPRC (0.30) | — | |
| SCHEMBL7516468 | 0.83 | — | — | |
| SCHEMBL5160584 | 0.83 | — | — | |
| SCHEMBL4450631 | 0.80 | — | — | |
| SCHEMBL16014041 | 0.79 | CRHBP (0.41) | KMT2AGAATSHRCRHBPCRHR2 | |
| SCHEMBL2572905 | 0.79 | MEN1 (0.31) | KMT2AMEN1 | |
| SCHEMBL7141745 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1405917-B1 | Process for the production of 3-Heteroaryl-3-hydroxy-propionic acid derivatives by enantioselective microbial reduction | SALTIGO GMBH (DE) | 2013-08-14 | — | — | EP | claimed |
| US-8293899-B2 | Ketone transfer hydrogenation of stereoisomerically enriched 3-heteroaryl-3-oxocarboxylic esters by reducing 3-heteroaryl-3-hydroxycarboxylic esters in the presence of a ruthenium-containing catalyst, an amine and formic acid and/or formates | LANXESS DEUTSCHLAND GMBH (DE) | 2012-10-23 | — | — | US | claimed |
| EP-1346977-B1 | Method for producing aryl-aminopropanols | SALTIGO GMBH (DE) | 2009-07-22 | — | — | EP | claimed |
| EP-1340746-B1 | Process for the reduction of 3-heteroaryl-3-oxo-propanoic acid derivatives | SALTIGO GMBH (DE) | 2007-02-28 | — | — | EP | claimed |
| US-20040181058-A1 | Process for preparing 3-heteroaryl-3-hydroxypropanoic acid derivatives | LANXESS DEUTSCHLAND GMBH (DE) | 2004-09-16 | — | — | US | claimed |
| US-20030225274-A1 | Process for reducing 3-heteroaryl-3-oxopropionic acid derivatives | LANXESS DEUTSCHLAND GMBH (DE) | 2003-12-04 | — | — | US | claimed |
| EP-1346977-A1 | Method for producing aryl-aminopropanols | Bayer Aktiengesellschaft (DE) | 2003-09-24 | — | — | EP | claimed |
| EP-1405917-B1 | Process for the production of 3-Heteroaryl-3-hydroxy-propionic acid derivatives by enantioselective microbial reduction | SALTIGO GMBH (DE) | 2013-08-14 | — | — | EP | disclosed |
| US-8293899-B2 | Ketone transfer hydrogenation of stereoisomerically enriched 3-heteroaryl-3-oxocarboxylic esters by reducing 3-heteroaryl-3-hydroxycarboxylic esters in the presence of a ruthenium-containing catalyst, an amine and formic acid and/or formates | LANXESS DEUTSCHLAND GMBH (DE) | 2012-10-23 | — | — | US | disclosed |
| US-7553970-B2 | Process for preparing 3-heteroaryl-3-hydroxypropanoic acid derivatives | LANXESS DEUTSCHLAND GMBH (DE) | 2009-06-30 | — | — | US | disclosed |
| US-20070259776-A1 | Preparation of Mono-N-sulphonylated diamines | LANXESS DEUTSCHLAND GMBH (DE) | 2007-11-08 | — | — | US | disclosed |
| US-7232927-B2 | Reacting diamine with sulfonyl halide of water, solvent and alkali or alkaline earth metal hydroxide or carbonate; sulfonamidation, salt formation | LANXESS DEUTSCHLAND GMBH (DE) | 2007-06-19 | — | — | US | disclosed |
| EP-1340746-B1 | Process for the reduction of 3-heteroaryl-3-oxo-propanoic acid derivatives | SALTIGO GMBH (DE) | 2007-02-28 | — | — | EP | disclosed |
| US-20060264641-A1 | Process for preparing 3-heteroaryl-3-hydroxypropanoic acid derivatives | BERENDES FRANK | 2006-11-23 | — | — | US | disclosed |
| US-20050059842-A1 | Reacting diamine with sulfonyl halide of water, solvent and base; sulfonamidation, salt formation; hydrogenation catalysts; metallization | LANXESS DEUTSCHLAND GMBH (DE) | 2005-03-17 | — | — | US | disclosed |
| US-20040181058-A1 | Process for preparing 3-heteroaryl-3-hydroxypropanoic acid derivatives | LANXESS DEUTSCHLAND GMBH (DE) | 2004-09-16 | — | — | US | disclosed |
| EP-1405917-A2 | Process for the production of 3-Heteroaryl-3-hydroxy-propionic acid derivatives by enantioselective microbial reduction | Bayer Chemicals AG (DE) | 2004-04-07 | — | — | EP | disclosed |
| US-20030225274-A1 | Process for reducing 3-heteroaryl-3-oxopropionic acid derivatives | LANXESS DEUTSCHLAND GMBH (DE) | 2003-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040181058-A1 | Process for preparing 3-heteroaryl-3-hydroxypropanoic acid derivatives | HPD, HAAO, GRHPR | KMT2A 1997/4885MEN1 4409/4885MGAM 584/4885 |
| US-20050059842-A1 | Reacting diamine with sulfonyl halide of water, solvent and base; sulfonamidation, salt formation; hydrogenation catalysts; metallization | SRM, SMOX, SLC6A12 | KMT2A 382/4885MEN1 548/4885MGAM 64/4885 |
| US-20030225274-A1 | Process for reducing 3-heteroaryl-3-oxopropionic acid derivatives | GRHPR, HPD, HAAO | KMT2A 1666/4885MEN1 4424/4885MGAM 323/4885 |
| US-20060264641-A1 | Process for preparing 3-heteroaryl-3-hydroxypropanoic acid derivatives | HPD, HAAO, GRHPR | KMT2A 1997/4885MEN1 4409/4885MGAM 584/4885 |
| US-20070259776-A1 | Preparation of Mono-N-sulphonylated diamines | SRM, SMOX, SMS | KMT2A 502/4885MEN1 881/4885MGAM 1201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.